[go: up one dir, main page]

SV2016005301A - Nuevos compuestos macrocíclicos - Google Patents

Nuevos compuestos macrocíclicos

Info

Publication number
SV2016005301A
SV2016005301A SV2016005301A SV2016005301A SV2016005301A SV 2016005301 A SV2016005301 A SV 2016005301A SV 2016005301 A SV2016005301 A SV 2016005301A SV 2016005301 A SV2016005301 A SV 2016005301A SV 2016005301 A SV2016005301 A SV 2016005301A
Authority
SV
El Salvador
Prior art keywords
macrocyclic compounds
new macrocyclic
compounds
prepare
general formula
Prior art date
Application number
SV2016005301A
Other languages
English (en)
Inventor
Ulrich Lücking
Pierre Wasnaire
Arne Scholz
Philip Lienau
Gerhard Siemeister
Christian Stegmann
Ulf Bömer
Kunzeng Zheng
Ping Gao
Jiajun Xi
Gang Chen
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52824234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2016005301(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SV2016005301A publication Critical patent/SV2016005301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

NUEVOS COMPUESTOS MACROCÍCLICOS DE LA FÓRMULA GENERAL (I) COMO SE LOS DESCRIBE Y SE LOS DEFINE EN LA MEMORIA DESCRIPTIVA. MÉTODOS PARA PREPARARLOS. SU USO EN EL TRATAMIENTO Y/O LA PROFILAXIS DE DIVERSOS TRASTORNOS, PARTICULARMENTE DE LOS TRASTORNOS HIPERPROLIFERATIVOS, DE LAS ENFERMEDADES INFECCIOSAS INDUCIDAS POR VIRUS Y/O DE LAS ENFERMEDADES CARDIOVASCULARES. COMPUESTOS INTERMEDIOS ÚTILES PARA PREPARAR LOS COMPUESTOS DE LA FÓRMULA GENERAL (I)
SV2016005301A 2014-04-11 2016-10-11 Nuevos compuestos macrocíclicos SV2016005301A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014000392 2014-04-11
PCT/EP2015/057546 WO2015155197A1 (en) 2014-04-11 2015-04-08 Novel macrocyclic compounds

Publications (1)

Publication Number Publication Date
SV2016005301A true SV2016005301A (es) 2018-03-12

Family

ID=52824234

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2016005301A SV2016005301A (es) 2014-04-11 2016-10-11 Nuevos compuestos macrocíclicos

Country Status (28)

Country Link
US (1) US9963464B2 (es)
EP (1) EP3129387B1 (es)
JP (1) JP6605493B2 (es)
KR (1) KR102383938B1 (es)
CN (1) CN106459084B (es)
AP (1) AP2016009483A0 (es)
AR (1) AR099999A1 (es)
AU (1) AU2015243585B2 (es)
BR (1) BR112016023554B1 (es)
CA (1) CA2945237C (es)
CL (1) CL2016002577A1 (es)
CR (1) CR20160471A (es)
CU (1) CU24399B1 (es)
DO (1) DOP2016000278A (es)
EA (1) EA032541B1 (es)
ES (1) ES2743799T3 (es)
IL (1) IL247966B (es)
MX (1) MX376962B (es)
PE (1) PE20161379A1 (es)
PH (1) PH12016501968A1 (es)
SG (1) SG11201608430RA (es)
SV (1) SV2016005301A (es)
TN (1) TN2016000435A1 (es)
TW (1) TW201623312A (es)
UA (1) UA119349C2 (es)
UY (1) UY36072A (es)
WO (1) WO2015155197A1 (es)
ZA (1) ZA201607765B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108290903B (zh) * 2015-09-29 2021-09-03 拜耳医药股份有限公司 新的大环磺酰二亚胺化合物
US10214542B2 (en) 2015-10-08 2019-02-26 Bayer Pharma Aktiengesellschaft Modified macrocyclic compounds
EA036551B1 (ru) * 2016-04-22 2020-11-23 Астразенека Аб Макроциклические ингибиторы mcl1 для лечения рака
RU2019111887A (ru) * 2016-10-20 2020-11-20 Пфайзер Инк. Антипролиферативные средства для лечения лаг
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CN109251212A (zh) * 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN111434665B (zh) * 2019-01-11 2023-03-10 上海长森药业有限公司 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
WO2023057812A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ304059B6 (cs) 2000-12-21 2013-09-11 Glaxo Group Limited Deriváty pyrimidinu a farmaceutický prostredek
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
BRPI0517426A (pt) 2004-12-17 2008-10-07 Astrazeneca Ab composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
MX2009006535A (es) 2006-12-22 2009-06-26 Novartis Ag Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
WO2008079933A2 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
WO2008129071A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
EP2137166B1 (en) 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
ES2539518T3 (es) 2007-04-24 2015-07-01 Astrazeneca Ab Inhibidores de proteínas quinasas
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
BR112012024017B1 (pt) 2010-03-22 2021-12-07 Lead Discovery Center Gmbh Compostos derivados de triazina dissubstituída farmaceuticamente ativos, composição farmacêutica, método para a síntese destes e uso dos mesmos
CN103562184B (zh) 2011-03-02 2016-04-27 利德探索中心有限公司 药学活性的二取代的吡啶衍生物
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
ES2587284T3 (es) * 2011-09-16 2016-10-21 Bayer Intellectual Property Gmbh 5-Fluoro-pirimidinas 2,4-disustituidas como inhibidores selectivos de CDK9
WO2013037894A1 (en) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
ES2597232T3 (es) 2012-10-18 2017-01-17 Bayer Pharma Aktiengesellschaft 4-(orto)-fluorofenil-5-fluoropirimidin-2-il aminas que contienen un grupo sulfona
HUE032868T2 (en) 2012-11-15 2017-11-28 Bayer Pharma AG 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
JP6300818B2 (ja) 2012-11-15 2018-03-28 バイエル ファーマ アクチエンゲゼルシャフト スルホキシイミン基を含有する４−（オルト）−フルオロフェニル−５−フルオロピリミジン−２−イルアミン
JP6371385B2 (ja) 2013-07-04 2018-08-08 バイエル ファーマ アクチエンゲゼルシャフト スルホキシイミン置換５−フルオロ−ｎ−（ピリジン−２−イル）ピリジン−２−アミン誘導体およびそのｃｄｋ９キナーゼ阻害薬としての使用
EP3116869A1 (en) 2014-03-13 2017-01-18 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group

Also Published As

Publication number Publication date
CU20160152A7 (es) 2017-04-05
AP2016009483A0 (en) 2016-10-31
AR099999A1 (es) 2016-08-31
JP6605493B2 (ja) 2019-11-13
ES2743799T3 (es) 2020-02-20
BR112016023554B1 (pt) 2023-03-14
IL247966A0 (en) 2016-11-30
CN106459084B (zh) 2019-04-19
CA2945237A1 (en) 2015-10-15
EA201692034A1 (ru) 2017-04-28
AU2015243585A1 (en) 2016-10-13
AU2015243585B2 (en) 2019-08-01
US9963464B2 (en) 2018-05-08
CA2945237C (en) 2022-09-06
WO2015155197A1 (en) 2015-10-15
DOP2016000278A (es) 2016-11-15
SG11201608430RA (en) 2016-11-29
IL247966B (en) 2021-02-28
BR112016023554A2 (pt) 2017-08-15
CN106459084A (zh) 2017-02-22
UY36072A (es) 2015-11-30
EP3129387A1 (en) 2017-02-15
US20170029439A1 (en) 2017-02-02
UA119349C2 (uk) 2019-06-10
PH12016501968A1 (en) 2016-12-19
EA032541B1 (ru) 2019-06-28
CR20160471A (es) 2016-12-21
KR20160136449A (ko) 2016-11-29
MX376962B (es) 2025-03-07
TN2016000435A1 (en) 2018-04-04
ZA201607765B (en) 2022-09-28
JP2017510598A (ja) 2017-04-13
PE20161379A1 (es) 2017-01-15
EP3129387B1 (en) 2019-06-26
TW201623312A (zh) 2016-07-01
CL2016002577A1 (es) 2017-04-07
MX2016013362A (es) 2017-02-09
CU24399B1 (es) 2019-04-04
KR102383938B1 (ko) 2022-04-08

Similar Documents

Publication Publication Date Title
SV2016005301A (es) Nuevos compuestos macrocíclicos
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
DOP2017000176A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
EP3960735C0 (en) QUINAZOLINE DERIVATIVES USED TO TREAT HIV
HUE058737T2 (hu) Eljárások arenaviridae vírusok okozta fertõzések kezelésére
UY36499A (es) Uso de picolinamidas como fungicidas
EA201790630A1 (ru) Способы получения рибозидов
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2015003140A (es) Formulaciones de enzalutamida.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016001543A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas.
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
PE20151142A1 (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina
UY36938A (es) Nuevos compuestos macrocíclicos modificados
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CR20160448A (es) Nuevos derivados de piridina
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
UY36923A (es) Nuevos compuestos macrocíclicos de sulfondiimina